Khiron Announces Partnership to Initiate the First Cannabis Clinical Research in Latin America and Expand Product Development to Address the Global Skincare Market
- Anticipated to materially advance efforts to meet consumer needs in the global $131 Billion USD skincare market (Source: Euromonitor International)
- First-ever cannabis clinical research study initiated in Latin America key to developing new dermo cosmetic and dermatological product lines for Khiron Skin Unit and strengthen Kuida® portfolio
- First mover advantage in development of dermo cosmetic products with cannabis worldwide
- Entered into multi-year agreement with Centro Dermatológico Federico Lleras Acosta (CDFLLA), leading Latin American institution, to jointly conduct medical cannabis research and host educational activities addressing skin conditions and symptoms
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQB:KHRNF), (Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that it has entered into an agreement with the prominent Colombian research hospital, Centro Dermatológico Federico Lleras Acosta (“CDFLLA”). Pursuant to the terms of the agreement, Khiron and CDFLLA will establish a clinical research partnership focused on the effectiveness of medical cannabis for dermatological conditions. Cannabis clinical trials performed by Khiron and CDFLLA will be the first such studies conducted in Latin America.
Khiron and CDFLLA will focus their efforts on studying and improving the methods of administering and prescribing cannabis as a potential supportive therapy for various skin conditions and symptoms. As part of the program, Khiron and CDFLLA will conduct training sessions, educational events and seminars focused on educating the medical community and patients on the safety and efficacy of medical cannabis. In addition, CDFLLA will also support Khiron in performing studies on cosmetic and cosmeceutical products manufactured and marketed by Khiron, through its subsidiary Kuida®, the first CBD consumer brand of skin and body care products launched in Latin America.
Dr. Claudia Rojas, Director of CDFLLA, comments: “A growing number of healthcare professionals believe that medical cannabis provides significant benefits for patients suffering from a range of dermatological conditions. Khiron and CDFLLA are committed to developing a body of scientific research that supports these findings in order to help patients manage their skin conditions and aid doctors in making informed healthcare decisions.”
Dr. Edwin Bendek, Khiron Medical Director, Skincare, comments: “Khiron is proud to work closely with the Centro Dermatológico Federico Lleras Acosta (“CDFLLA”) to pioneer cannabis research in Latin America. With the launch of our Kuida brand, the first CBD-based cosmeceutical brand in Latin America, combined with our partnership with CDFLLA, we are closer to achieving our mission of bringing safe and medically-validated medical cannabis products to market.”
The partnership with CDFLLA reinforces Khiron’s commitment to a patient-oriented operational model, which aims to engage and educate healthcare professionals and patients on the benefits of medical cannabis. It also expands Khiron’s efforts in the skincare sector, where the Company has focused on innovating and introducing CBD-based cosmeceutical products to the global market through a rigorous and research-based product development strategy. The agreement establishes a three-year partnership between Khiron and CDFLLA, with the option to extend at the conclusion of the original period.
About Centro Dermatológico Federico Lleras Acosta (CDFLLA)
Centro Dermatológico Federico Lleras Acosta (CDFLLA) is a University Hospital of the National Order which provides specialized dermatology outpatient services that focus on health promotion, disease prevention, humanization, patient safety and sustainability, within the Integrated System Management. Since its inception in 1934, CDFLLA has worked to promote education, research and comprehensive training specialists, and has become a widely respected place of training recognized at both the national and international levels. CDFLLA has also served to advise the national government on public policy in dermatology, for the purpose of improving the health of Colombians.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/
To be added to the distribution list, please email email@example.com with “Khiron” in the subject line.
Market and Industry Data
This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the anticipated benefits of the distribution agreements, including online and physical retail consumer exposure, and potential expansion into other jurisdictions, among others. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United Statesor to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: firstname.lastname@example.org; Phil Carlson, KCSA Strategic Communications, 212-896-1233, E: email@example.com; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: firstname.lastname@example.org
The post Khiron Announces Partnership to Initiate the First Cannabis Clinical Research in Latin America and Expand Product Development to Address the Global Skincare Market appeared first on Investing News Network.